# Phase III Study of TS-142 in Patients with Insomnia

> **NCT05453136** · PHASE3 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 1155 (actual)

## Conditions studied

- Patients with Insomnia

## Interventions

- **DRUG:** TS-142 5 mg
- **DRUG:** TS-142 10 mg
- **DRUG:** Placebo to TS-142

## Key facts

- **NCT ID:** NCT05453136
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-30
- **Primary completion:** 2023-12-05
- **Final completion:** 2023-12-05
- **Target enrollment:** 1155 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453136, "Phase III Study of TS-142 in Patients with Insomnia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05453136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*